(2S)-2-({4-[(2S)-1-(2-Amino-4-oxo-1,4-dihydro-6-quinazolinyl)-3-{[2-({(2R,3R,4S,5R)-3,4-dihydroxy-5-[(phosphonooxy)methyl]tetrahydro-2-furanyl}amino)-2-oxoethyl]amino}-2-hydroxy-2-propanyl]benzoyl}ami no)pentanedioic acid
Star0
Identification
- Generic Name
- (2S)-2-({4-[(2S)-1-(2-Amino-4-oxo-1,4-dihydro-6-quinazolinyl)-3-{[2-({(2R,3R,4S,5R)-3,4-dihydroxy-5-[(phosphonooxy)methyl]tetrahydro-2-furanyl}amino)-2-oxoethyl]amino}-2-hydroxy-2-propanyl]benzoyl}ami no)pentanedioic acid
- DrugBank Accession Number
- DB02794
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 752.6197
Monoisotopic: 752.205451056 - Chemical Formula
- C30H37N6O15P
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UPhosphoribosylglycinamide formyltransferase Not Available Escherichia coli (strain K12) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as glycinamide ribonucleotides. These are compounds in which the amide N atom of glycineamide is linked to the C-1 of a ribosyl (or deoxyribosyl) moiety. Nucleotides have a phosphate group linked to the C5 carbon of the ribose (or deoxyribose) moiety.
- Kingdom
- Organic compounds
- Super Class
- Nucleosides, nucleotides, and analogues
- Class
- Glycinamide ribonucleotides
- Sub Class
- Not Available
- Direct Parent
- Glycinamide ribonucleotides
- Alternative Parents
- Pentose phosphates / Glutamic acid and derivatives / Stilbenes / Hippuric acids / N-acyl-alpha amino acids / Alpha amino acid amides / Quinazolinamines / Monosaccharide phosphates / Benzoyl derivatives / Aminopyrimidines and derivatives show 22 more
- Substituents
- 1,2-aminoalcohol / Alcohol / Alkyl phosphate / Alpha-amino acid amide / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aminopyrimidine / Aralkylamine show 51 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- N-glycosyl compound, ribose monophosphate, quinazolines, N-acyl-L-alpha-amino acid, L-glutamic acid derivative (CHEBI:39574)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- QZUCAWXKEZPFBV-PRICPSHJSA-N
- InChI
- InChI=1S/C30H37N6O15P/c31-29-34-18-6-1-14(9-17(18)26(43)36-29)10-30(46,16-4-2-15(3-5-16)25(42)33-19(28(44)45)7-8-22(38)39)13-32-11-21(37)35-27-24(41)23(40)20(51-27)12-50-52(47,48)49/h1-6,9,19-20,23-24,27,32,40-41,46H,7-8,10-13H2,(H,33,42)(H,35,37)(H,38,39)(H,44,45)(H2,47,48,49)(H3,31,34,36,43)/t19-,20+,23+,24+,27+,30+/m0/s1
- IUPAC Name
- (2S)-2-({4-[1-(2-amino-4-oxo-1,4-dihydroquinazolin-6-yl)-3-[({[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]carbamoyl}methyl)amino]-2-hydroxypropan-2-yl]phenyl}formamido)pentanedioic acid
- SMILES
- [H]N([H])C1=NC(=O)C2=C(C=CC(CC(O)(CN([H])CC(=O)N([H])[C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C3=CC=C(C=C3)C(=O)N([H])[C@@H](CCC(O)=O)C(O)=O)=C2)N1[H]
References
- General References
- Not Available
- External Links
- PubChem Compound
- 446514
- PubChem Substance
- 46508046
- ChemSpider
- 393847
- ZINC
- ZINC000098207915
- PDBe Ligand
- 138
- PDB Entries
- 1jkx
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0905 mg/mL ALOGPS logP -1.1 ALOGPS logP -4.5 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 1.21 Chemaxon pKa (Strongest Basic) 8.14 Chemaxon Physiological Charge -3 Chemaxon Hydrogen Acceptor Count 18 Chemaxon Hydrogen Donor Count 12 Chemaxon Polar Surface Area 348.99 Å2 Chemaxon Rotatable Bond Count 17 Chemaxon Refractivity 174.94 m3·mol-1 Chemaxon Polarizability 70.58 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.8976 Blood Brain Barrier - 0.8178 Caco-2 permeable - 0.7157 P-glycoprotein substrate Substrate 0.7476 P-glycoprotein inhibitor I Non-inhibitor 0.7968 P-glycoprotein inhibitor II Non-inhibitor 0.9954 Renal organic cation transporter Non-inhibitor 0.8582 CYP450 2C9 substrate Non-substrate 0.8472 CYP450 2D6 substrate Non-substrate 0.8012 CYP450 3A4 substrate Substrate 0.5312 CYP450 1A2 substrate Non-inhibitor 0.7888 CYP450 2C9 inhibitor Non-inhibitor 0.8303 CYP450 2D6 inhibitor Non-inhibitor 0.8541 CYP450 2C19 inhibitor Non-inhibitor 0.8183 CYP450 3A4 inhibitor Non-inhibitor 0.8098 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8777 Ames test Non AMES toxic 0.5704 Carcinogenicity Non-carcinogens 0.9071 Biodegradation Not ready biodegradable 0.9808 Rat acute toxicity 2.7383 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7636 hERG inhibition (predictor II) Non-inhibitor 0.5159
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 236.60468 predictedDeepCCS 1.0 (2019) [M+H]+ 238.35493 predictedDeepCCS 1.0 (2019) [M+Na]+ 244.65735 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Unknown
- General Function
- Phosphoribosylglycinamide formyltransferase activity
- Specific Function
- Catalyzes the transfer of a formyl group from 10-formyltetrahydrofolate to 5-phospho-ribosyl-glycinamide (GAR), producing 5-phospho-ribosyl-N-formylglycinamide (FGAR) and tetrahydrofolate.
- Gene Name
- purN
- Uniprot ID
- P08179
- Uniprot Name
- Phosphoribosylglycinamide formyltransferase
- Molecular Weight
- 23238.065 Da
References
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52